| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.99 |
| Leukemia |
0 |
0.67 |
| Cancer |
0 |
0.45 |
| Genomic Medicine |
0 |
0.41 |
| Toxicology |
0 |
0.34 |
| Blood |
0 |
0.28 |
| Lymphoma |
0 |
0.23 |
| Remission |
0 |
0.23 |
| Acute Leukemia |
0 |
0.13 |
| Acute Lymphoblastic Leukemia |
0 |
0.12 |
| Patient Safety |
0 |
0.12 |
| Antigens |
0 |
0.11 |
| Gene Editing |
0 |
0.11 |
| Hospital |
0 |
0.11 |
| Transplantation |
0 |
0.11 |
| Bridge to Transplantation |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.08 |
| Adverse Effects |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Medicaid |
0 |
0.06 |
| Medicare |
0 |
0.06 |
| Neurotoxicity |
0 |
0.06 |
| Prognosis |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |